Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: A biphasic relationship with tumour grade

Journal of Pathology

Volumn 188, Issue 4, 1999, Pages 382-388

  Bouras, Toula ^b   Frauman, Albert G ^a  

^a AUSTIN HEALTH   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

KAI1; Metastasis; Neoplasia; Prostate; Tumour suppressor gene

Indexed keywords

ARTICLE; CANCER GRADING; CHROMOSOME 11P; GENE EXPRESSION REGULATION; GENE LOCATION; HUMAN; HUMAN TISSUE; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

EID: 0032796610     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199908)188:4<382::AID-PATH365>3.0.CO;2-O     Document Type: Article

References (28)

1. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (Wash DC) 1995; 268: 884-886.
2. Gavgitsch HW, Hofer E, Huber NE, Schnabal E, Baumruker TA. A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23. Eur J Immunol 1991; 21: 377-383.
3. Gil ML, Vita N, Lebel-Binay S, et al. A member of the tetra spans transmembrane protein superfamily is recognised by a monoclonal antibody raised against an HLA class I-deficient, lymphokine activated killer-susceptible, B lymphocyte line. J Immunol 1992; 148: 2825-2833.
4. Nojima Y, Hirose T, Tachibana K., et al. The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T-cell activation and adhesion. Cell Immunol 1993; 152: 249-260.
5. Imai T, Fukudome K, Takagi S, et al. C33 antigen recognised by monoclonal antibody inhibitory to human T cell leukemia virus type I-induced syncytium formation is a member of a new family of transmembrane proteins, including CD9, CD37, CD53 and CD63. J Immunol 1992; 149: 2879-2886.
6. Wright MD, Tomlinson MG. The ins and outs of the transmembrane 4 superfamily. Immunol Today 1994; 15: 588-594.
7. Hotta H, Ross AH, Huebner K, et al. Molecular cloning and characterisation of an antigen associated with early stages of melanoma tumour progression. Cancer Res 1988; 48: 2955-2962.
8. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP1/CD9) DNA. J Exp Med 1993; 177: 1231-1237.
9. Dong JT, Suzuki H, Pin SS, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56: 4387-4390.
10. Ueda U, Ichikawa T, Tamaru J, et al. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 1996; 149: 1435-1440.
11. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273-279.
12. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
13. Major B, Cures A, Frauman AG. The full length and splice variant thyrotropin receptor is expressed exclusively in skeletal muscle of extraocular origin: a link to the pathogenesis of Graves' ophthalmopathy. Biochem Biophys Res Commun 1997; 230: 493-496.
14. Ichikawa T, Ichikawa Y, Isaacs JT. Genetic factors and suppression of metastatic ability of prostate cancer. Cancer Res 1991; 51: 3788-3792.
15. Ichikawa T, Nihei N, Suzuki H, et al. Suppression of metastasis of rat prostate cancer by introducing human chromosome 8. Cancer Res 1994; 54: 2299-2302.
16. Ichikawa T, Ichikawa Y, Dong J-T, et al. Localisation of metastasis suppressor gene(s) for prostate cancer to short arm of human chromosome 11. Cancer Res 1992; 52: 3886-3890.
17. Isaacs WB, Bova SG, Morton RA, Bussemarkes MJG, Brooks JD, Ewing CM. Molecular genetics and chromosomal alterations in prostate cancer. Cancer 1995; 75: 2004-2012.
18. Edelstein RA, Krane RJ, Babayan R, Morenas A, Moreland RB. A rapid and simple method for the detection of prostate specific antigen mRNA in archival tissue specimens using reverse transcriptase-polymerase chain reaction. Urology 1995; 45: 597-603.
19. Horikoshi T, Danenberg KD, Stadlbauer THW, et al. Quantitation of thymidylate synthase, dihydofolate reductase and DT-diaphorase gene expression in human tumours using the polymerase chain reaction. Cancer Res 1992; 52: 108-116.
20. Adachi M, Taki T, Leki Y, Huang C-I, Higashiyama M, Miyake M. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996; 56: 1751-1755.
21. Guo X, Friess H, Graber HU, et al. KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res 1996; 56: 4876-4880.
22. Lebel-Binay S, Laguandriere C, Fradelizi P, Conjeaud H. CD82, tetra-spantransmembrane protein is a regulated transducing molecule on U937 monocytic cell line. J. Leuk Biol 1995; 57: 956-963.
23. Sokoloff MH, Tso C-L, Kaboo R, et al. In vitro modulation of tumour progression associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 1996; 77: 1862-1872.
24. Nagira M, Imai T, Ishikawa I, Uwabe KI, Yoshie O. Mouse homologue of C33 antigen (CD82), a member of the transmembrane 4 superfamily; complementary DNA, genomic structure, and expression. Cell Immunol 1994; 157: 144-157.
25. de Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poisez B, Baylin SB. The short arm of chromosome 11 is a 'hot spot' for hypermethylation in human neoplasia. Proc Natl Acad Sci U S A 1988; 85: 5693-5697.
26. Miyake M, Nakano K, Ieki Y, et al. Motility related protein 1 (MRP1/CD9) expression: inverse correlation with metastasis in breast cancer. Cancer Res 1995; 55: 4127-4131.
27. Si Z, Hersey P. Expression of the neuroglandular antigen and analogues in melanoma: CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer 1993; 54: 37-43.
28. Higashiyama M, Taki T, Ieki Y, et al. Reduced motility related protein (MRP1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 1995; 55: 6040-6044.